Artemisinin and its derivatives are the most potent anti-malaria drugs.Nevertheless, artemisinin monotherapy is associated with accumulation of dormant ring stages and with recrudescence of Plasmodium infection, which is considered a treatment failure.The molecular mechanism(s) leading to parasite dormancy are under investigation.Here we report that dormancy is associated with phosphorylation of the parasite's eukaryotic initiation factor-2α (eIF2α).In an attempt to reveal which one of three Plasmodium kinases, eIK1, eIK2, or PK4 is involved we generated knockouts of the enzymes.Following artesunate treatment, the eIK1(-) and eIK2(-) parasites phosphorylated their eIF2α and entered dormancy like wild type.We could not obtain knockouts of PK4 because it is essential for blood stage development where the gene targeting takes place.Nevertheless minutes after drug treatment PK4 dimerized, autophosphorylated and phosphorylate eIF2α indicating that it is the enzyme that controls dormancy.Artesunate-induced dormancy is extended by salubrinal, a selective inhibitor of the eIF2α-P phosphatases, which provides evidence for the mechanism that Plasmodium phophorylates eIF2α causing dormancy in response to artemisinin treatment.